Prognostic factors in hodgkin lymphoma

Stefan Hohaus, Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Manuela Giachelia

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

24 Citazioni (SciVal)


Hodgkin lymphoma (HL) is among the neoplastic diseases that has the best long-term outcome after cytotoxic treatment. Cure rates approach 80-90%; however, 15-20% of patients will be resistant to therapy (primary refractory) or relapse after treatment. Prognostic factors should help to stratify treatment according to the risk profile and identify patients at risk for failure. Significance of prognostic factors partly depends on the efficacy of the treatments administered, since new effective therapies can variably counterbalance the adverse effects of some unfavorable clinical determinants. As a consequence, some prognostic factors thought to be important in the past may become meaningless when modern successful therapies are used. Therefore, the value of prognostic factors has to be updated periodically, and then adapted to new emerging biomarkers. Besides the prognostic role of PET imaging, tissue and circulating biomarkers, as the number of tumor-infiltrating macrophages, cytokine and chemokine levels and profiling of circulating nucleic acids (DNA and microRNAs) have shown promise.
Lingua originaleEnglish
pagine (da-a)2014053-2014062
Numero di pagine10
RivistaMediterranean Journal of Hematology and Infectious Diseases
Stato di pubblicazionePubblicato - 2014


  • Hodgkin lymphoma
  • Prongostic factors


Entra nei temi di ricerca di 'Prognostic factors in hodgkin lymphoma'. Insieme formano una fingerprint unica.

Cita questo